Table 1.
Inhibition of β-haematin formation and parasite activity in CQ-sensitive (PfNF54) and multidrug-resistant (PfK1) strains of P. falciparum of top-ranked USFDA approved drugs selected on the basis of their ranking in a previously published Bayesian model [15].
| Bayesian Rank |
Drug | β-haematin IC50 (μM) |
PfNF54 IC50 (µM) |
PfK1 IC50 (µM) |
RI 2 |
|---|---|---|---|---|---|
| 1 | Lapatinib | 5.43 ± 0.03 | 0.26 ± 0.07 | 0.85 ± 0.02 | 3.3 |
| 2 | Amodiaquine | 21 4 | NT 3 | 0.0086 5 | - |
| 3 | Imatinib | 99 ± 5 | 3.9 ± 0.1 | NT 3 | - |
| 4 | Nafarelin | 48 ± 5 | NA 1 | NT 3 | - |
| 5 | Nilotinib | 7 ± 1 | 0.28 ± 0.02 | 0.38 ± 0.06 | 1.4 |
| 6 | Antrafenine | NT 3 | NT 3 | NT 3 | - |
| 7 | Vapreotide | 48 ± 7 | NA 1 | NT 3 | - |
| 8 | Gefitinib | 20.4 ± 0.8 | 11.5 ± 0.4 | NT 3 | - |
| 13 | Thiabendazole | > 500 | NA 1 | NT 3 | - |
| 14 | Erlotinib | 17.6 ± 0.2 | 13.3 ± 0.4 | NT 3 | - |
| 19 | Lomitapide | 68.2 ± 0.9 | 0.56 ± 0.10 | 0.69 ± 0.14 | 1.2 |
| 21 | Chloroquine | 26 ± 0.3 | 0.015 ± 0.001 | 0.272 ± 0.005 | 18 |
| 1505 | Dantrolene | >500 | NT 3 | NT 3 | - |
| 1506 | Nitrendipine | >500 | NT 3 | NT 3 | - |
| 1508 | Nimodipine | >500 | NT 3 | NT 3 | - |
| 1510 | Acenocumarol | >500 | NT 3 | NT 3 | - |